FRIDAY, July 30, 2021 (HealthDay News) — Death rates from Alzheimer’s disease are particularly high in the rural United States, a preliminary study finds, highlighting a need for health care resources in traditionally under-served areas. Researchers discovered that over the past two decades, rural areas in the Southeast have seenContinue Reading

WEDNESDAY, July 28, 2021 (HealthDay News) — An outside advisor to the U.S. Food and Drug Administration’s review of the controversial Alzheimer’s drug Aduhelm is now speaking out, arguing that the approval was based on dodgy science and involved questionable collaboration between regulators and the drug’s maker. “I’m not surprisedContinue Reading

TUESDAY, July 27, 2021 (HealthDay News) — While efforts to develop Alzheimer’s medications have so far borne little fruit, new research highlights the therapeutic promise of two non-drug tools: light and sound. According to a pair of small new studies, exposing Alzheimer’s patients to an hour a day of carefullyContinue Reading

FRIDAY, July 23, 2021 (HealthDay News) — The controversial new Alzheimer’s drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about whether they should take the medication. Many doctors believe the U.S. Food and DrugContinue Reading

FRIDAY, July 23, 2021 (HealthDay News) — A drug that eases hallucinations in people with Parkinson’s disease may be able to do the same for those with dementia, a new clinical trial finds. The medication, called Nuplazid (pimavanserin), is already approved in the United States for treating hallucinations and delusionsContinue Reading

TUESDAY, July 20, 2021 (HealthDay News) — Women on hormone replacement therapy (HRT) for menopause go on to have a 58% lower risk of Alzheimer’s disease and other neurodegenerative conditions, a new study finds. Although the study wasn’t designed to prove cause and effect, the findings could point the wayContinue Reading

THURSDAY, July 15, 2021 (HealthDay News) — Two major U.S. health systems say they will not administer the controversial new Alzheimer’s drug Aduhelm. The decisions by the Cleveland Clinic and Mount Sinai’s Health System in New York City are the latest fallout from the U.S. Food and Drug Administration’s widelyContinue Reading